Novo

U.S. demand for Novo Nordisk’s weight loss drugs is so huge that the Danish central bank just doubled the nation’s entire growth forecast

"The growth is mainly due to Novo’s sales and production in the U.S. market at the beginning of this year."

Fortune•Eleanor Pringle4h ago

Ozempic-maker Novo open to upgrading US listing

Boss Mike Doustdar says he sees ‘advantages’ in giving US investors direct access to Danish group’s stock

Financial Times11h ago

• neutral toward Novo · 97%

STAT+: Did the Trump administration just cut Novo a huge financial win?

The White House's GENEROUS plan was designed to make drugs more affordable for Medicaid users. There's one glaring potential exception.

STAT•John Wilkerson22h ago

• favorable toward Novo · 75%
• critical toward Donald Trump · 66%

Novo CEO says pills could capture 50% of weight-loss market by 2030

• neutral toward Novo · 98%

STAT+: Novo may be getting a better deal than expected with Medicare’s Bridge program

Eli Lilly and Novo Nordisk were already benefitting a great deal from the Trump administration's pilot program covering obesity drugs for seniors at a price of $245 a month. It…

STAT•Elaine Chen22 Sept

• favorable toward Novo · 91%

<a href="https://www.fiercebiotech.com/medtech/siemens-healthineers-team-novo-fatty-liver-disease-awareness-blood-testing" hreflang="en">Siemens Healthineers and Novo team up on fatty liver disease awareness, testing</a>

Siemens Healthineers is joining forces with Novo to help boost awareness and diagnosis of fatty liver disease.

Fierce Biotech•Ben Adams22 Sept

• neutral toward Novo · 98%

Novo CEO signals M&A opportunities to strengthen drug pipeline

Novo CEO Mike Doustdar told CNBC that it is considering M&A opportunities as it faces growing competition in the weight-loss market.

CNBC22 Sept

• neutral toward Novo · 93%

Siemens Healthineers and Novo join forces to advance care for people living with MASLD and MASH

Siemens Healthineers and Novo have announced a collaboration focused on advancing care for people living with metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH).

• neutral toward Novo · 98%

Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production

Eli Lilly is trying to catch up in the GLP-1 pill market to Novo, which got a head start in the space.

CNBC21 Sept

<a href="https://www.fiercepharma.com/pharma/novo-aims-appease-investors-direct-consumer-plans-blockbuster-ambitions" hreflang="en">Novo struggles to appease restive investors with consumer plans, blockbuster ambitions</a>

With reports leaking out of investor discontent, CEO Mike Doustdar opened Novo's Capital Markets Day by acknowledging that the company’s leadership “have to convince” the audience that “there is a bright future for Novo.”

Fierce Pharma•James Waldron, Fraiser Kansteiner21 Sept

• critical toward Novo · 95%

<a href="https://www.fiercebiotech.com/pharma/novo-aims-appease-investors-direct-consumer-plans-blockbuster-ambitions" hreflang="en">Novo struggles to appease restive investors with consumer plans, blockbuster ambitions</a>

With reports leaking out of investor discontent, CEO Mike Doustdar opened Novo's Capital Markets Day by acknowledging that the company’s leadership “have to convince” the audience that “there is a bright future for Novo.”

Fierce Biotech•James Waldron, Fraiser Kansteiner21 Sept

• critical toward Novo · 96%

STAT+: Pharmalittle: We’re reading about Novo plans to expand its pipeline, early Alkermes ADHD data, and more

Novo Nodisk outlined plans to expand its pipeline and find new products that it could sell more like consumer goods than traditional medicines

STAT•Andrew Joseph21 Sept

• neutral toward Novo · 96%

Novo says CagriSema tops Lilly rival in diabetes patients for weight loss

• neutral toward Novo · 97%

STAT+: With new strategy, Novo outlines plans for obesity, direct-to-consumer work

Under investor pressure, Novo presented its strategy to both grow its obesity franchise and diversify its pipeline.

STAT•Andrew Joseph21 Sept

• neutral toward Novo · 94%

Novo stock falls as much as 7% despite $23 billion sales target for blockbuster obesity drugs

CNBC21 Sept

• neutral toward Novo · 98%

Wegovy-maker Novo faces calls to map out strategy beyond weight-loss drugs

• neutral toward Novo · 90%

<a href="https://www.fiercebiotech.com/biotech/refreshed-novo-corrals-three-new-early-stage-obesity-drugs-kallyope" hreflang="en">Refreshed Novo corrals 3 new early-stage obesity drugs from Kallyope</a>

New-look Novo is digging deeper into its metabolic roots with three new obesity programs purchased from New York biotech Kallyope.

Fierce Biotech•Darren Incorvaia18 Sept

• neutral toward Novo · 88%

<a href="https://www.fiercepharma.com/pharma/europes-chmp-endorses-slew-new-medicines-including-novo-and-az-new-offerings" hreflang="en">Europe's CHMP endorses slew of new medicines, including new offerings from Novo and AZ</a>

The CHMP recommendation for Novo's next gen hemophilia A treatment was one of several noteworthy endorsements made by the EU agency this week.

Fierce Pharma•Donavyn Coffey18 Sept

• favorable toward Novo · 70%

<a href="https://www.fiercebiotech.com/pharma/still-bull-novos-ceo-honoring-heritage-and-planning-future-amid-corporate-rebrand" hreflang="en">'Still a bull': Novo's CEO on honoring heritage and planning for the future amid corporate rebrand</a>

Novo CEO Mike Doustdar—tapped to breathe new life into the Danish drugmaker last year after losing GLP-1 marketing ground to chief rival Eli Lilly—isn’t one to make changes for the sake of change.

Fierce Biotech•Fraiser Kansteiner17 Sept

• neutral toward Novo · 78%

<a href="https://www.fiercepharma.com/pharma/still-bull-novos-ceo-honoring-heritage-and-planning-future-amid-corporate-rebrand" hreflang="en">'Still a bull': Novo's CEO on honoring heritage and planning for the future amid corporate rebrand</a>

Novo CEO Mike Doustdar—tapped to breathe new life into the Danish drugmaker last year after losing GLP-1 marketing ground to chief rival Eli Lilly—isn’t one to make changes for the sake of change.

Fierce Pharma•Fraiser Kansteiner17 Sept

• neutral toward Novo · 78%